Everest Medicines Limited (1952.HK)

HKD 50.8

(3.15%)

EBITDA Summary of Everest Medicines Limited

Everest Medicines Limited's latest annual EBITDA in 2023 was -744.62 Million CNY , up 53.0% from previous year.
Everest Medicines Limited's latest quarterly EBITDA in 2024 Q2 was -324.27 Million CNY , down 0.0% from previous quarter.
Everest Medicines Limited reported an annual EBITDA of -198.91 Million CNY in 2022, down -52.0% from previous year.
Everest Medicines Limited reported an annual EBITDA of -972.77 Million CNY in 2021, up 82.67% from previous year.
Everest Medicines Limited reported a quarterly EBITDA of -324.27 Million CNY for 2024 Q1, down -63.13% from previous quarter.
Everest Medicines Limited reported a quarterly EBITDA of -198.78 Million CNY for 2023 Q4, down 0.0% from previous quarter.

Annual EBITDA Chart of Everest Medicines Limited (2023 - 2018)

Historical Annual EBITDA of Everest Medicines Limited (2023 - 2018)

Year	EBITDA	EBITDA Growth
2023	-744.62 Million CNY	53.0%
2022	-198.91 Million CNY	-52.0%
2021	-972.77 Million CNY	82.67%
2020	-683.02 Million CNY	-2389.03%
2019	-195.72 Million CNY	77.11%
2018	-126.37 Million CNY	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	-324.27 Million CNY	0.0%
2024 Q1	-324.27 Million CNY	-63.13%
2023 Q4	-198.78 Million CNY	0.0%
2023 Q2	-203.63 Million CNY	0.0%
2023 FY	- CNY	53.0%
2023 Q1	-203.63 Million CNY	48.24%
2023 Q3	-198.78 Million CNY	2.38%
2022 Q3	-393.4 Million CNY	-30.25%
2022 Q4	-393.4 Million CNY	0.0%
2022 Q2	-302.04 Million CNY	0.0%
2022 FY	- CNY	-52.0%
2022 Q1	-302.04 Million CNY	6.73%
2021 Q3	-323.85 Million CNY	-63.82%
2021 Q2	-197.68 Million CNY	0.0%
2021 FY	- CNY	82.67%
2021 Q1	-197.68 Million CNY	4.62%
2021 Q4	-323.85 Million CNY	0.0%
2020 FY	- CNY	-2389.03%
2020 Q3	-207.25 Million CNY	77.32%
2020 Q2	-913.71 Million CNY	-396.88%
2020 Q4	-207.25 Million CNY	0.0%
2020 Q1	307.77 Million CNY	0.0%
2019 FY	- CNY	77.11%
2019 Q1	101.32 Million CNY	0.0%
2018 FY	- CNY	0.0%

Peer EBITDA Comparison of Everest Medicines Limited

Name	EBITDA	EBITDA Difference
Uni-Bio Science Group Limited	91.23 Million HKD	916.174%
CK Life Sciences Int'l., (Holdings) Inc.	486.79 Million HKD	252.965%